Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

NCT02269163 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Immunodeficiency

Interventions

BIOLOGICAL: Immune Globulin Intravenous
BIOLOGICAL: Prometic's Immune Globulin Intravenous 10%

Sponsor

Prometic Biotherapeutics, Inc.

Collaborators

[object Object]